Merck Beats Revenue Estimates and Raises 2026 Outlook

Merck Group reported second-quarter financial results on Tuesday, exceeding revenue estimates with $16.61 billion, marking a 5% increase from the previous year. The growth was primarily driven by the performance of new products and the immunotherapy drug Keytruda, which contributed $8.37 billion to the total. Based on these results, the company increased its 2026 revenue outlook to a range between $66.3 billion and $67.3 billion.

Despite the revenue growth, the company lowered its adjusted profit guidance to between $2.66 and $2.76 per share, a significant drop from the previous estimate of $5.04 to $5.16. This reduction stems from one-time charges associated with two major acquisitions: the $5.7 billion purchase of Terns Pharmaceuticals and the $9 billion acquisition of Cidara Therapeutics.

Merck is currently pursuing an aggressive expansion of its portfolio through these acquisitions and new drug launches, including a recently approved PCSK9 pill. These strategic moves are intended to offset the impact of future generic competition facing its diabetes medications, Januvia and Janumet, as well as Keytruda.